Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Eyepoint Inc Focuses Is A Clinical-Stage Biopharmaceutical Company Committed To Developing And Commercializing Therapeutics To Improve The Lives Of Patients With Serious Retinal Diseases, That May Reduce The Frequency Of Follow-Up Care. The Company'S Pipeline Program Includes I) Duravyu: A Sustained-Release Product Candidate For Retinal Diseases, With The Potential To Provide Patients With Improved Visual Outcomes With Less Burden. Ii) Eyp-2301: Early-Stage Program Using Durasert E Technology To Deliver Razuprotafib, A Tie-2 Agonist Targeting Ve-Ptp For Vascular Stability In Retinal Diseases Like Wet Amd.